Disease Pompe: report of case

Enfermedad de Pompe: reporte de caso

Objective. It is a case of a seven months male patient, evaluated by cardiology fifteen days after he was born secondary, to sudden cardiac death of his sister of four months, nothing suspicious despite consanguinity of parents and early diagnosis of the patient with Cardiomyopathy. Evolved with the following clinical conditions recurrent respiratory infections from three months (recurrent bronchiolitis), widespread malnutrition and recent pneumonia. Died eight days after the consultation with the geneticist. Methods. The initial approach was to perform echocardiogram at fifteen days old, because of history of the sudden death of his sister of four months, cardiomegaly and parental consanguinity. Clinical deterioration continues through months so he is referred to genetic, enzymatic tests, taken in dried blood, the patient dies before receiving the diagnosis of Pompe disease. Results. The patient was focused with a possible diagnosis of Pompe Disease so lysosomal enzyme α -glucosidase (GAA) sample was requested in dried blood and genetic sequencing final report to define diagnosis.

1. Bravo-Oro, A. Diagnóstico e intervenciones terapéuticas en la enfermedad de Pompe. Rev Med Inst Mex Seguro Soc. 2013; 51(5): 536-51
2. Byrne, BJ; Kishnani, PS; Case, LE; Merlini, L; MüllerFelber, W; Prasad, S; et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab. 2011; 103(1):1-11.
3. Jeong-A, L; Lishu, L; Nina, R. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014; 6(177).
4. Ans, T; Van der Ploeg, M; Clemens, P; Corzo, D. A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe’s Disease. N Engl J Med. 2010; 362:1396-1406.
5. Rare Disease Act 2002. An Act to amend the Public Health Service Act to establish an Office of Rare Diseases at the National Institutes of Health, and for other purposes. November 6, 2002.
6. Cortes, F. Las enfermedades raras. Revista médica Clínica Las Condes. 2015; 26(4): 425-431.
7. Chien, Y; Hwu, WY; Lee, NY. Pompe Disease: Early Diagnosis and Early Treatment Make a Difference. Pediatrics & Neonatology. 2013; 54(4); 219-227.
8. Sepp, E; Reuser, A; Lohi, H. A Nonsense Mutation in the Acid α-Glucosidase Gene Causes Pompe Disease in Finnish and Swedish Lapphunds. PLOS ONE 2013.
9. Van, Carla. Newborn screening for pompe disease? a qualitative study exploring professional views. BMC Pediatr. 2014; 14(203)
10. Leslie, N; Tinkle, BT. Glycogen Storage Disease Type II
11. (Pompe Disease). University of Washington, Seattle. 2007
12. Cupler, EJ; Berger, KI; Leshner, RT. AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012; 45:319–33.
13. American College of Medical Genetics. Pompe disease diagnosis and management guideline. Disponible en http://www.nature.
14. com/gim/journal/v8/n5/abs/gim200650a.html. 2006.
15. Weinreich, SS; Rigter, T; Van El, CG; Dondorp, WJ. Public support for neonatal screening for Pompe disease, a broadphenotype condition. Orphanet J Rare Dis. 2012; 7(15).
16. Ross, LF; Waggoner, DJ. Parents: critical stakeholders in expanding newborn screening. J Pediatr. 2012; 161(3):385-9.
17. Dubrovsky, A; Fulgenzi, E; Amartino, H; Carlés, D; Corderi, J; De Vito, E. Consenso argentino para el diagnóstico, seguimiento y tratamiento de la enfermedad de Pompe. Neurología Argentina. 2014; 6(2): 96-113.
18. Han, S; Pope, R; Li, S; Kishnani, P; Steet, R; Koeberl, D. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease. Molecular Genetics and Metabolism. 2016; 117(2):114-119.
19. Nausa, J. G. (2014). “Evaluación Clínica y radiográfica de injertos biocerámicos tipo Hidroxiapatita como alternativa en la reconstrucción de alveolos dentarios postexodoncia.”
20. Millan, J. and L. Yunda (2014). “An Open-Access Web-based medical image atlas for collaborative Medical image sharing, processing, Web Semantic searching and analysis with uses in medical training, research and second opinion of cases.” Nova 12(22): 143-150.
21. ==========================================
22. DOI: http://dx.doi.org/10.22490/24629448.1743